The Role of the Vosoritide Drug in Childrens with Achondroplasia

Achondroplasia is a hereditary disorder that follows an autosomal dominant inheritance pattern. The condition is a result of harmful mutations in the FGFR3 gene, which occur when there are two different versions of the gene presentMutations in the de novo gene FGFR3 prevent the development of chondrocytes forward unregulated growth and instead promote the growth of existing bone,this negatively affects the creation of new bone. Vosoritide, additionally called voxzogo, represents a significant leap approaching the approval of a pharmaceutical treatment that is specifically intended to address achondroplasia. Aforementioned medication has been approved for use in-home injections, these injections must be conducted under the supervision of a knowledgeable nurse in ordering to ensure proper guidance and safety.